LUNA-EMG to Enhance Motor Functions in Neurological Disorders

Study of the Efficacy of the LUNA-EMG System on Motor Function in the Management of Neurological Disorders.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04716829

Acronym

LUNA

Enrollment

Registered

2021-01-20

Start date

2021-03-01

Completion date

2024-12-31

Last updated

2025-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

stroke, EMG, rehabilitation, physiotherapy, occupational therapy

Brief summary

The aim of the present study is to evaluate the effects of training performed with the LUNA-EMG system to enhance motor functions of the upper limb in stroke This is a randomized open-label trial. Patients will be randomized into the intervention group (LUNA-EMG) or in the control group (standard care). The effect of the training will be measured with the EMG, the upper limb motor function and the quality of life.

Interventions

DEVICELUNA-EMG

The LUNA-EMG (Samcom) system is a robot that allows the evaluation of muscular strength through the recording of muscle activity (electromyography - EMG) in order to provide precise objective data on the patient's muscle function. In addition to the diagnostic aspect (evaluation of muscle strength, range of motion and proprioception), the LUNA-EMG robot allows the adaptation of movements during rehabilitation sessions according to the individually generated strength.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult * Having signed the informed consent

Exclusion criteria

* Acute pain syndrome * Severe cognitive deficits * Risk of fracture or unconsolidated fracture * Rigid joints (spasticity, severe osteoarthritis and arthritis) or unstable joints * Severe ataxia and apraxia * Epilepsy * Pacemakers and similar implants * Insufficient skin conditions

Design outcomes

Primary

Measure	Time frame	Description
muscular strength in mV	12 weeks	muscular strength will be measured with the EMG

Secondary

Measure	Time frame	Description
Fugl-Meyer	12 weeks	The scale evaluates motor capacities of the upper limb following a stroke. Scores range from 0 to 66 (the higher the better).
Modified Ashworth Scale	12 weeks	This scale measures spasticity. The results are scored from 0 to 4 (the higher the more spastic).
Lovett	12 weeks	This scale measures muscular strength. The scale ranges from 0 to 5 (the higher the better).

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026